|
rs1042028
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs1057519771
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CHMFL-ABL-039 has demonstrated greater efficacies than Imatinib regarding to the anti-proliferation, inhibition of the signaling pathway, arrest of cell cycle progression, induction of apoptosis in vitro and suppression of the tumor progression in vivo in the native and V299L mutated BCR-ABL kinase-driven cells/xenograft models.
|
30894066 |
2019 |
|
rs55958994
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression.
|
31328168 |
2019 |
|
rs7121
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this review and meta-analysis, we focus on the synonymous SNP rs7121 (<i>FokI</i>, c.393C>T), which is associated with either tumor progression or prolonged survival in cancer patients (overall hazard ratio = 2.256; p < 0.001).
|
31124412 |
2019 |
|
rs9282861
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs11672691
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found an association of the aggressive PCa-associated allele G of rs11672691 with elevated transcript levels of two biologically plausible candidate genes, PCAT19 and CEACAM21, implicated in PCa cell growth and tumor progression.
|
30033361 |
2018 |
|
rs121918464
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The E76K GOF mutation is the most common and active SHP2 mutation; however, the pathogenic effects and function of this mutation in CRC tumor progression have not been well characterized.
|
29323748 |
2018 |
|
rs145204276
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The allele del of rs145204276 is associated with a remarkably lower incidence of cancer progression and metastasis.
|
29557411 |
2018 |
|
rs28934578
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Gain-of-function p53 mutants such as p53-R175H form stable aggregates that accumulate in cells and play important roles in cancer progression.
|
29593334 |
2018 |
|
rs562015640
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The E76K GOF mutation is the most common and active SHP2 mutation; however, the pathogenic effects and function of this mutation in CRC tumor progression have not been well characterized.
|
29323748 |
2018 |
|
rs762807774
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
|
29679610 |
2018 |
|
rs200863613
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Dysfunction of individual annexin and S100A proteins is associated with cancer progression, metastasis and cancer drug resistance.
|
28068434 |
2017 |
|
rs969139366
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.
|
28541695 |
2017 |
|
rs121913279
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results suggest PIK3CA H1047R mutant cells have a selective advantage in breast, contribute to breast cancer susceptibility, and drive tumor progression during breast carcinogenesis, even when present as only a subpopulation of tumor cells.
|
27108388 |
2016 |
|
rs2057482
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, the rs2057482-CC genotype increases the susceptibility to PDAC and associated with cancer progression.
|
26872370 |
2016 |
|
rs557263543
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs869320694
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs961150162
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs11568818
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The -181A→G (rs11568818) polymorphism in the MMP7 promoter modulates gene expression and possibly affects cancer progression.
|
25847246 |
2015 |
|
rs104893626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
|
24711662 |
2014 |
|
rs11549465
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Hypoxia-inducible factor-1 (HIF-1) influences cancer progression and metastasis through various mechanisms, and HIF-1α polymorphisms are reportedly associated with many cancers; however, the associations of HIF-1α P582S and A588T polymorphisms with the risk of digestive system cancer remain inconclusive.
|
24293391 |
2014 |
|
rs11549467
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Hypoxia-inducible factor-1 (HIF-1) influences cancer progression and metastasis through various mechanisms, and HIF-1α polymorphisms are reportedly associated with many cancers; however, the associations of HIF-1α P582S and A588T polymorphisms with the risk of digestive system cancer remain inconclusive.
|
24293391 |
2014 |
|
rs1273593548
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
|
rs2016347
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In multivariable analysis, patients with primary invasive breast cancer carrying IGF1R_rs2016347 G allele had a significantly increased risk of early tumor progression (hazard ratio (HR) 2.01; adjusted P=0.004) and death (HR 1.84; adjusted P=0.023) compared with patients carrying G/T or T/T, independent of established clinicopathological determinants.
|
23459444 |
2014 |
|
rs4444235
|
|
|
0.010 |
GeneticVariation |
BEFREE |
LOH analysis suggested that the three CRC risk variants, rs12657484, rs3802842, and rs4444235, exhibited somatic allele-specific imbalance and might be critical during neoplastic progression.
|
24968322 |
2014 |